Tirapazamine-cisplatin: the synergy.
Tirapazamine is a novel bioreductive agent with selective cytotoxicity against hypoxic tumour cells. Synergy with cisplatin and other chemotherapeutic agents has been shown in preclinical trials. Pharmacokinetic studies of tirapazamine have revealed that exposure increases with dose over the range o...
Main Authors: | Gatzemeier, U., Rodriguez, G., Treat, J., Miller, V., von Roemeling, R., Viallet, J., Rey, A. |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
1998
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149886/ |
Similar Items
-
Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
by: Brown, J. M.
Published: (1998) -
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
by: Patterson, A. V., et al.
Published: (1995) -
Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
by: Siim, B. G., et al.
Published: (1996) -
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
by: Brown, J. M.
Published: (1993) -
Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
by: Khan, S., et al.
Published: (1995)